Rasagiline is primarily used in the treatment of Parkinson's disease. It functions as a monoamine oxidase-B (MAO-B) inhibitor, which helps to increase dopamine levels in the brain by preventing its breakdown. This action helps to alleviate symptoms such as tremors, stiffness, and slowness of movement. It can be used as a standalone therapy in early-stage Parkinson's or as an adjunct to other treatments like levodopa in more advanced stages. Additionally, rasagiline has been studied for its potential neuroprotective properties, which may slow the progression of the disease. It is typically administered orally in tablet form, offering convenience for long-term management of Parkinson's symptoms.